Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
BioProcess Internation...BioProcess International US West
Not Confirmed
Not Confirmed
09-11 March, 2026
BioProcess Internation...BioProcess International
Not Confirmed
Not Confirmed
09-11 March, 2026
Not Confirmed
Not Confirmed
09-11 March, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS




Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
BioProcess Internation...BioProcess International US West
Industry Trade Show
Not Confirmed
09-11 March, 2026
BioProcess Internation...BioProcess International
Industry Trade Show
Not Confirmed
09-11 March, 2026
Industry Trade Show
Not Confirmed
09-11 March, 2026
Digital content

11 Feb 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/akesos-il-4rst2-bispecific-antibody-cleared-for-seven-phase-ii-studies-in-china-spanning-respiratory-and-autoimmune-indications-302684870.html

30 Jan 2026
// PRESS RELEASE
https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Announces-U-S--FDA-Acceptance-of-Biologics-License-Application-BLA-Seeking-Approval-for-Ivonescimab-in-Combination-with-Chemotherapy-in-Treatment-of-Patients-with-EGFRm-NSCLC-Post-TKI-Therapy/default.aspx

19 Jan 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/akeso-announces-nmpa-acceptance-of-second-nda-for-gumokimab-il-17a-inhibitor-in-active-ankylosing-spondylitis-302664371.html

10 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/updated-efficacy-data-of-ivonescimab-combined-with-chemotherapy-as-first-line-treatment-for-tnbc-presented-at-esmo-io-2025-302638641.html

09 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/phase-ii-data-of-cadonilimab-regimen-as-neoadjuvant-therapy-for-resectable-gastric-cancer-presented-at-esmo-asia-2025-302636294.html

07 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/all-approved-indications-of-five-akesos-innovative-drugs-included-in-chinas-latest-nrdl-featuring-two-first-in-class-bispecifics-with-new-first-line-indications-and-three-newly-negotiated-drugs-302634722.html
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE